Does Wegovy Always Work — and What Affects the Results?

What 'it works for most people' actually means in numbers

The pivotal STEP 1 trial followed 1,961 adults with obesity over 68 weeks. Those taking semaglutide 2.4 mg lost an average of around 15% of their starting body weight, compared with roughly 2.4% in the placebo group, a result published in the New England Journal of Medicine and later reviewed by NICE. That 15% figure is a mean, though. Within the trial, outcomes spread widely: some people lost over 20%, others closer to 5%. About one in ten participants on active treatment lost less than 5% of their body weight over the full study period.

So the question isn't simply whether Wegovy works. It's whether it will work well enough for you, in your circumstances, at the right dose. That's a clinical judgement, not a guarantee, and it's the reason a prescriber needs to assess you before treatment starts and continues to review you throughout. If you want to understand the underlying mechanism, our page on how Wegovy works covers the GLP-1 pathway in plain terms.

One thing worth knowing early: results rarely arrive in week one, and our page on when Wegovy works explains what the evidence says about the timeline from first dose to meaningful change. The dose you start on (0.25 mg) is designed to help your body adjust, not to drive weight loss immediately.

Three factors that genuinely shape whether Wegovy works for you

Thinking of this as a yes/no question misses the real picture. There are at least three modifiable and non-modifiable factors that influence how well semaglutide works for any individual.

Biology and genetics. GLP-1 receptor sensitivity varies between people. Some individuals respond strongly to even modest doses; others reach the maximum dose and still find the appetite-suppressing effect less pronounced. This isn't a personal failing, it reflects the same pharmacological variability seen with most medicines.

Adherence and titration. Wegovy is titrated up over several months. Missing doses, not reaching the maintenance dose, or stopping early (often because of side effects in the first few weeks) all reduce the likelihood of a strong result. Our page on how long Wegovy takes to work sets realistic expectations for the early weeks, which is when most people feel tempted to give up.

Lifestyle alongside treatment. The licence explicitly combines semaglutide with a reduced-calorie diet and increased physical activity. Trial participants received structured behavioural support too. Wegovy is not a replacement for those elements, it makes them easier to sustain by reducing appetite, but the two work together. People who change very little about their eating or movement patterns tend to see smaller results.

The NHS medicines page for semaglutide covers what the treatment involves and what to expect during the titration period.

When NICE says it may be time to reconsider

If you've reached and stayed on the maintenance dose for six months and lost less than 5% of your starting weight, NICE's recommendation for semaglutide (TA875) suggests that continuing treatment should be reviewed. That threshold exists because the evidence for benefit at very low response rates is weaker, and the cost-benefit calculation shifts.

This isn't a cliff edge, it's a clinical conversation. Your prescriber might look at whether you've actually reached a stable maintenance dose, whether something else is affecting your response (certain medications, thyroid conditions, stress), or whether a different approach would suit you better. Some people who plateau at 2.4 mg may be candidates for the newly approved 7.2 mg dose, subject to clinical assessment. For a broader look at how semaglutide fits into the wider landscape of weight-management medicines, that page is a useful starting point.

It's also worth knowing that some people find the cold sensitivity that can accompany significant weight loss (covered in our page on feeling cold on Wegovy) to be an unexpected sign that the treatment is, in fact, working.

The decision in front of you

If you're reading this because you're wondering whether it's worth starting, or because you've been on Wegovy for a few weeks and aren't sure you're seeing enough, that's an entirely understandable place to be. Weight loss medicine attracts both hype and scepticism, and it can be hard to know what to expect from a real treatment in a real body.

The evidence says Wegovy works for most people at a clinically meaningful level. It also says results are not uniform, they take time, and they depend partly on factors you can influence. Whether it's the right choice for you, and at what dose, is exactly what a prescriber is there to work through. You can explore the full range of weight-loss treatment options available through a regulated UK service, or look at the cost of Wegovy if that's part of your thinking. When you're ready, speak to our prescribers, there's no fee for the consultation, and a real clinician reads your answers the same day.